Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs

Expert Opinion on Drug Delivery

Volumn 4, Issue 6, 2007, Pages 665-675

  Lacko, Andras G ^a   Nair, Maya ^a   Prokai, Laszlo ^a   McConarthy, Walter J ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer chemotherapy; Drug delivery; Lipoprotein; Targeting

Indexed keywords

ACLACINOMYCIN; AMPHOTERICIN B; ANTHRACYCLINE DERIVATIVE; ANTIBODY CONJUGATE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; CHOLESTEROL ESTER; CREMOPHOR; DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; OMEGA 3 FATTY ACID; PACLITAXEL; PEPTIDE FRAGMENT; SERUM ALBUMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALRUBICIN; WB 4291;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER CHEMOTHERAPY; CANCER THERAPY; COMPLEX FORMATION; COVALENT BOND; DRUG ACTIVITY; DRUG ANALYSIS; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; FEASIBILITY STUDY; FINANCIAL MANAGEMENT; HUMAN; HYDROPHOBICITY; INVESTMENT; MACROMOLECULE; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; NEOPLASMS;

EID: 36649031633     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.6.665     Document Type: Review

References (118)

1. ROSEN H, ABRIBAT T: The rise and rise of drug delivery. Nat. Rev. Drug Discov. (2005) 4(5):381-385.
2. MINCHINTON AI, TANNOCK IF: Drug penetration in solid tumours. Nat. Rev. Cancer (2006) 6(8):583-592.
3. YIH TC, Ll-FANDI M: Engineered nanoparticles as precise drug delivery systems. J. Cell Biochem. (2006) 97(6):1184-1190.
4. COX MC, DAN TD, SWAIN SM: Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin. Emerging Drugs (2006) 11(3):489-501.
5. BLAY JY, LE CESNE A, ALBERTI L, RAY-COQUART I: Targeted cancer therapies. Bull Cancer (2005) 92(2):E13-E18.
6. TULENKO TN, SUMNER AE: The physiology of lipoproteins. J. Nucl. Cardiol. (2002) 9(6):638-649.
7. HEVONOJA T, PENTIKAINEN MO, HYVONEN MT, KOVANEN PT, ALA-KORPELA M: Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim. Biophys. Acta (2000) 1488(3):189-210.
8. WANG M, BRIGGS MR: HDL: The metabolism, function, and therapeutic importance. Chem. Rev. (2004) 104:119-137.
9. HO YK, SMITH RG, BROWN MS, GOLDSTEIN JL: Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood (1978) 52(6):1099-1114.
10. KRIEGER M, SMITH LC, ANDERSON RG et al.: Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. J. Supramol. Struct. (1979) 10(4):467-478.
11. PUSSINEN PJ, KARTEN B, WINTERSPERGER A et al.: The human breast carcinoma cell line HBL-L00 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem. J. (2000) 349(2):559-566.
12. LACKO AG, NAIR M, PARANJAPE S, JOHNSON S, MCCONATHY WJ: High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. (2002) 22(4):2045-2049.
13. COUNSELL RE, POHLAND RC: Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem. (1982) 25(10):111-125.
14. IMACHI H, MURAO K, SAYO Y et al.: Evidence for a potential role for HDL as an important source of cholesterol in human adrenocortical tumors via the CLA-1 pathway. Endocr. J. (1999) 46(1):27-34.
15. GAL D, OHASHI M, MACDONALD PC, BUCHSBAUM HJ, SIMPSON ER: Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am. J. Obstet. Gynecol. (1981) 139(8):877-885.
16. LUNDBERG B: Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res. (1987) 47(15):4105-4108.
17. CAO WM, MURAO K, IMACHI H et al.: A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. (2004) 64(4):1515-1521.
18. LACKO AG, NAIR M, PARANJAPE S, MCCONATHY WJ: Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy (2006) 52(4):171-173.
19. KRIEGER M, BROWN MS, FAUST JR, GOLDSTEIN JL: Replacement of endogenous cholesteryl esters of low density lipoprotein with exogenous cholesteryl linoleate. Reconstitution of a biologically active lipoprotein particle. J. Biol. Chem. (1978) 253(12):4093-4101.
20. MASQUELIER M, TIRZITIS G, PETERSON CO et al.: Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur. J. Med. Chem. (2000) 35(40):429-438.
21. MASQUELIER M, LUNDBERG B, PETERSON CO, VITOLS SG: Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells. Leuk. Res. (2006) 30(2):136-144.
22. TATIDIS L, MASQUELIER M, VITOLS SG: Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem. Pharmacol. (2002) 63(12):2169-2180.
23. KADER A, PATER AJ: Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Rel. (2002) 80(1-3):29-44.
24. DE SMIDT PC, VAN BERKEL TJ: LDL-mediated drug targeting. Crit. Rev. Ther. Drug Carrier Syst. (1990) 7(2):99-120.
25. VITOLS S, GAHRTON G, OST A, PETERSON C: Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood (1984) 63(5):1186-1193.
26. GAL D, MACDONALD PC, PORTER JC, SIMPSON ER: Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism. Int. J. Cancer (1981) 28(3):315-319.
27. VITOLS S, ANGELIN B, ERICSSON S et al.: Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Natl. Acad. Sci. USA (1990) 87(7):2598-2602.
28. CLAYMAN RV, BILHARTZ LE, SPADY DK, BUJA LM, DIETSCHY JM: Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue. FEBS Lett. (1986) 196(1):87-90.
29. FABRICANT M, BROITMAN SA: Evidence for deficiency of low density lipoprotein receptor on human colonic carcinoma cell lines. Cancer Res. (1990) 50(3):632-636.
30. ANDERSON RG, BROWN MS, GOLDSTEIN JL: Inefficient internalization of receptor-bound low density lipoprotein in human carcinoma A-431 cells. J. Cell Biol. (1981) 88(2):441-452.
31. RUDLING M, GAFVELS M, PARINI P, GAHRTON G, ANGELIN B: Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. Am. J. Pathol. (1998) 153(2):1923-1935.
32. MASQUELIER M, VITOLS S, PETERSON C: Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res. (1986) 46(8):3842-3847.
33. VITOLS S, GAHRTON G, PETERSON C: Significance of the low-density lipoprotein (LDL) receptor pathway for the in vitro accumulation of AD-32 incorporated into LDL in normal and leukemic white blood cells. Cancer Treat. Rep. (1984) 68(3):515-520.
34. VITOLS S, SÖDERBERG-REID K, MASQUELIER M, SJÖSTRÖM B, PETERSON C: Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br. J. Cancer (1990) 62(5):724-729.
35. TATIDIS L, MASQUELIER M, VITOLS S: Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem. Pharmacol. (2002) 63(12):2169-2180.
36. MASQUELIER M, VITOLS S, PALSSON M, MARS U, LARSSON BS, PETERSON C: Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J. Drug Target. (2000) 8(3):155-164.
37. VITOLS S, MASQUELIER M, PETERSON C: Selective uptake of a toxic lipophilic anthracycline derivative by the low-density lipoprotein receptor pathway in cultured fibroblasts. J. Med. Chem. (1985) 28(4):451-454.
38. MASQUELIER M, TIRIYIS G, PETERSON C et al.: Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur. J. Med. Chem. (2000) 35(4):429-438.
39. LO EH, OOI VE, FUNG KP: Circumvention of multidrug resistance and reduction of cardiotoxicity of doxorubicin in vivo by coupling it with low density lipoprotein. Life Sci. (2002) 72(6):677-687.
40. CHU AC, TSANG SY, LO EH, FUNG KP: Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Life Sci. (2001) 70(5):591-601.
41. JORI G, REDDI E: The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int. J. Biochem. (1993) 25(10):1369-1375.
42. ALLISON BA, PRITCHARD PH, LEVY JG: Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br. J. Cancer (1994) 69(5):833-839.
43. HAMMEL M, LAGGNER P, PRASSL R: Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system. Chem. Phys. Lipids (2003) 123(2):193-207.
44. MENG QH, WAHALA K, ADLERCREUTZ H, TIKKANEN MJ: Antiproliferative efficacy of lipophilic soy isoflavone phytoestrogens delivered by low density lipoprotein particles into cultured U937 cells. Life Sci. (1999) 65(16):1695-1705.
45. LESTAVEL-DELATTRE S, MARTIN-NIZARD F, CLAVEY V et al.: Low-density lipoprotein for delivery of an acrylophenouse antineoplastic molecule into malignant cells. Cancer Res. (1992) 52(13):3629-3635.
46. SQALLI-HOUSSAIN H, PIERLOT C, KUSNIERZ JP et al.: Preparation of anti-HIV-low-density lipoprotein complexes for delivery of anti-HIV drugs via the low-density lipoprotein pathways. Biotechnol. Ther. (1994) 5:69-85.
47. LI H, GRAY BD, CORBIN I et al.: MR and fluorescent imaging of low-density lipoprotein receptors. Acad. Radiol. (2004) 11(11):1251-1259.
48. ADAMS T, ALANAZI F, LU DR: Safety and utilization of blood components as therapeutic delivery systems. Curr. Pharm. Biotechnol. (2003) 4(5):275-282.
49. OWENS MD, BAILLIE G, HALBERT GW: Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences. Int. J. Pharm. (2001) 228(1-2):109-117.
50. SHAW JM, SHAW KV: Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier. Target. Diagn. Ther. (1991) 5:351-383.
51. WALSH MT, ATKINSON D: Reassembly of low-density lipoproteins. Methods Enzymol. (1986) 128:582-608.
52. RENSEN PC, DE VRUEH RL, KUIPER J, BIJSTERBOSCH MK, BIESSEN EA, VAN BERKEL TJ: Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. (2001) 47(2-3):251-276.
53. LUNDBERG B, SUOMINEN L: Preparation of biologically active analogs of serum low density lipoprotein. J. Lipid Res. (1984) 25(6):550-558.
54. LUNDBERG B: Abstract cytotoxic activity of two new lipophilic steroid nitrogen carbamates incorporated into low-density lipoprotein. Anticancer Drug Des. (1994) 9(5):471-476.
55. RENSEN PC, SCHIFFELERS RM, VERSLUIS AJ, BIJSTERBOSCH MK, VAN KUIJK-MEUWISSEN ME, VAN BERKEL TJ: Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol. Pharmacol. (1997) 52(3):445-455.
56. VERSLUIS AJ, RENSEN PC, RUMP ET, VAN BERKEL TJ, BIJSTERBOSCH MK: Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. Br. J. Cancer (1998) 78(12):1607-1614.
57. MARANHAO RC, CESAR TB, PEDROSO-MARIANI SR, HIRATA MH, MESQUITA CH: Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids (1993) 28(8):691-696.
58. LO PRETE AC, MARIA DA, RODRIGUES DG, VALDUGA CJ, IBANEZ OC, MARANHAO RC: Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nano-emulsion. J. Pharm. Pharmacol. (2006) 58(6):801-808.
59. RODRIGUES DG, MARIA DA, FERNANDES DC et al.: Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol. (2005) 55(6):565-576.
60. DIAS ML, CARVALHO JP, RODRIGUES DG, GRAZIANI SR, MARANHAO RC: Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother. Pharmacol. (2007) 59(1):105-111.
61. BAILLIE G, OWENS MD, HALBERT GW: A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. J. Lipid Res. (2002) 43(1):69-73.
62. NIKANJAM M, BLAKELY EA, BJORNSTAD KA, SHU X, BUDINGER TF, FORTE TM: Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int. J. Pharm. (2006) 328(1):86-94.
63. BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232(4746):34-47.
64. MARKEL A, BROOK GJ: Cancer and hypocholesterolemia. Isr. J. Med. Sci. (1994) 30(10):787-793.
65. FIORENZA AM, BRANCHI A, SOMMARIVA D: Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int. J. Clin. Lab. Res. (2000) 30(3):141-145.
66. DESSI S, BATETTA B, PULISCI D, ACCOGLI P, PANI P, BROCCIA G: Total and HDL cholesterol in human hematologic neoplasms. Int. J. Hematol. (1991) 54(6):483-486.
67. MOSCHOVI M, TRIMIS G, APOSTOLAKOU F, PAPASSOTIRIOU I, TZORZTATOU-STATHOPOLOU F: Serum lipid alterations in acute lymphoblastic leukemia of childhood. Pediatr. Hematol. Oncol. (2004) 26(5):289-293.
68. SCRIBANO D, BARONI S, PAGANO L, ZUPPI C, LEONE G, GIARDINA B: Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica (1996) 81(4):343-345.
69. SIEMIANOVICZ K, GMINSKI J, STAJSZCZYK M et al.: Serum LDL cholesterol concentration and lipoprotein electrophoresis pattern in patients with small cell lung cancer. Int. J. Mol. Med. (2000) 6(3):307-311.
70. BAYERDÖRFER E, MANNES GA, RICHTER WO et al.: Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann. Intern. Med. (1993) 118(7):481-487.
71. FIDGE NH: High density lipoprotein receptors, binding proteins, and ligands. J. Lipid Res. (1999) 40(2):187-201.
72. MURAO K, TERPSTRA V, GREEN SR, KONDRATENKO N, STEINBERG D, QUEHENBERGER O: Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J. Biol. Chem. (1997) 272(28):17551-17557.
73. RIGOTTI A, KRIEGER M: Getting a handle on "good" cholesterol with the high-density lipoprotein receptor. N. Engl. J. Med. (1999) 341(26):2011-2013.
74. FAVRE G, TAZI KA, LE GAILLARD F, BENNIS F, HACHEM H, SOULA G: High density lipoprotein-3 binding sites are related to DNA biosynthesis in the adenocarcinoma cell line A549. J. Lipid Res. (1993) 34(7):1093-1106.
75. GOSPODAROWICZ D, LUI GM, GONZALEZ R: High-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined medium. Cancer Res. (1982) 42(9):3704-3713.
76. JOZAN S, FAYE JC, TOURNIER JF, TAUBER JP, DAVID JF, BAYARD F: Interaction of estradiol and high density lipoproteins on proliferation of the human breast cancer cell line MCF-7 adapted to grow in serum free conditions. Biochem. Biophys. Res. Commun. (1985) 133(1):105-112.
77. WADSACK C, HIRSCHMUGL B, HAMMER A et al.: Scavenger receptor class B, type I on non-malignant and malignant human epithelial cells mediates cholesteryl ester-uptake from high density lipoproteins. Int. J. Biochem. Cell Biol. (2003) 35(4):441-454.
78. WADSACK C, HRZENJAK A, HAMMER A et al.: Trophoblast-like human choriocarcinoma cells serve as a suitable in vitro model for selective cholesteryl ester uptake from high density lipoproteins. Eur. J. Biochem. (2003) 270(3):451-462.
79. BARTER PJ: Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler. Suppl. (2002) 3(4):39-47.
80. LINSEL-NITSCHKE P, TALL AR: HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. (2005) 4(3):193-205.
81. HAMILTON RL, WILLIAMS MC, FIELDING CJ, HAVEL RJ: Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver. J. Clin. Invest. (1976) 58(3):667-680.
82. FORTE T, NORUM KR, GLOMSET JA, NICHOLS AV: Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: structure of low and high density lipoproteins as revealed by elctron microscopy. J. Clin. Invest. (1971) 50(5):1141-1148.
83. LERCH PG, FORTSCH V, HODLER G, BOLLI R: Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox. Sang. (1996) 71(3):155-164.
84. PARKER TS, LEVINE DM, CHANG JC, LAXER J, COFFIN CC, RUBIN AL: Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. (1995) 63(1):253-258.
85. 13C NMR studies of lysine ionization behavior. J. Biol. Chem. (1992) 267(36):25839-25847.
86. JONAS A, WALD JH, TOOHILL KL, KRUL ES, KEZDY KE: Apolipoprotein A-I structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. J. Biol. Chem. (1990) 265(36):22123-22129.
87. SCHOUTEN D, VAN DER KOOIJ M, MULLER J, PIETERS MN, BIJSTERBOSCH MK, VAN BERKEL TJ: Development of lipoprotein-like lipid particles for drug targeting: neo-high density lipoproteins. Mol. Pharmacol. (1993) 44(2):486-492.
88. BIJSTERBOSCH MK, SCHOUTEN D, VAN BERKEL TJ: Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry (1994) 33(47):14073-14080.
89. LOU B, LIAO XL, WU MP, CHENG PF, YIN CY, FEI Z: High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J. Gastroenterol. (2005) 11(7):954-959.
90. ODA MN, HARGREAVES PL, BECKSTEAD JA, REDMOND KA, VAN ANTWERPEN R, RYAN RO: Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J. Lipid Res. (2006) 47(2):260-267.
91. WANG R, FU Y, LAI L: A new atom-additive method for calculating partition coefficients. J. Chem. Inf. Comput. Sci. (1997) 37:615-621.
92. ZHENG G, CHEN J, LI H, GLICKSON JD: Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl. Acad. Sci. USA (2005) 102(49):17757-17762.
93. NUJIEN B, BOUMA M, SCHELLENS JH, BEIJNEN JH: Progress in the development of alternative pharmaceutical formulations of taxanes. Invest. New Drugs (2001) 19(12):143-53.
94. SINGLA AK, GARG A, AGGARWAL D: Paclitaxel and its formulations. Int. J. Pharm. (2002) 235(1-2):179-192.
95. TORCHILIN VP: Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate. Adv. Drug Deliv. Rev. (2005) 57(1):95-109.
96. STRIETH S, EICHHORN ME, SAUER B et al.: Neovascular targeting chemotherapy: encapsulation of paclitaxel so cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer (2004) 110(1):117-124.
97. FETTERLY GJ, STRAUBINGER RM: Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS Pharm. Sci. (2003) 5(4):E32.
98. MU L, FENG SS: A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Rel. (2003) 86(1):33-48.
99. GUILLEMARD V, SARAGOVI HU: Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. (2001) 61(2):694-699.
100. LUNDBERG BB: A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J. Pharm. Pharmacol. (1997) 49(1):16-21.
101. CHORDIA MD, YUAN H, JAGTAP PG et al.: Synthesis and bioactivity of 2,4-diacyl analogues of paclitaxel. Bioorg. Med. Chem. (2001) 9(1):171-178.
102. DE GROOT FM, VAN BERKOM LW, SCHEEREN HW: Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. J. Med. Chem. (2000) 43(16):3093-3102.
103. SAFAVY A, BONNER JA, WAKSAL HW et al.: Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug. Chem. (2003) 14(2):302-310.
104. LEE JW, LU JY, LOW PS, FUCHS PL: Synthesis and evaluation of Taxol-folic acid conjugates as targeted antineoplastics. Bioorg. Med. Chem. (2002) 10(7):2397-2414.
105. BRADLEY MO, WEBB NL, ANTHONY FH et al.: Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res. (2001) 7(10):3229-3238.
106. SUGAHARA S, KAJIKIM, KURIYAMA H, KOBAYASHI TR: Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol. Pharm. Bull. (2002) 25(5):632-641.
107. WU X, OJIMA I: Tumor specific novel taxoid-monoclonal antibody conjugates. Curr. Med. Chem. (2004) 11(4):429-438.
108. IBRAHIM NK, DESAI N, LEGHA S et al.: Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. (2002) 8(5):1038-1044.
109. DAMASCELLI B, CANTU G, MATTAVELLI F et al.: Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer (2001) 92(10):2592-2602.
110. BISOENDIAL RJ, HOVINGH GK, LEVELS JH et al.: Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 107(23):2944-2948.
111. NANJEE MN, CROUSE JR, KING JM et al.: Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. (1996) 16(9):1203-1214.
112. SPIEKER LE, SUDANO I, HÜRLIMANN D et al.: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation (2002) 105(12):1399-1402.
113. HOVORKA R, NANJEE MN, COOKE CJ, MILLER IP, OLSZEWSKI WL, MILLER NE: Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans. J. Lipid Res. (2006) 47(5):975-981.
114. NANJEE MN, CROUSE JR, KING JM et al.: Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. (1996) 16(9):1203-1214.
115. PAJKRT D, DORAN JE, KOSTER F et al.: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. (1996) 184(5):1601-1608.
116. PALATINI P: Disposition kinetics of phospholipid liposomes. Adv. Exp. Med. Biol. (1992) 318:375-391.
117. EDWARDS IJ, BERQUIN IM, SUN H et al.: Differential effects of delivery of ω-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin. Clin. Cancer Res. (2004) 10(24):8275-8283.
118. LACKO AG, STEWART DR, MCCLAIN R, PROKAI L, MCCONATHY WJ: Recent developments and patenting of lipoprotein based formulations. Recent Patents on Drug Delivery Formulation (2007) 1:143-145.